GlassScriptPhysician profile
Scott M Lieberman
NPI 1326038159
$4,969.82
in general payments reported to CMS, 2019-2025
32 companies · $692 in 2025
The $692 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $585 · 2020: $184 · 2021: $778 · 2022: $833 · 2023: $796 · 2024: $1,101 · 2025: $692.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,590.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,589.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $546.97 | 2019-2025 | |
| Abiomed | $439.13 | 2019-2022 | |
| Abbott Laboratories | $413.25 | 2023-2024 | Mitraclip, Optis, Perclose Prostyle |
| Merck Sharp & Dohme LLC | $372.10 | 2021-2024 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $352.95 | 2019-2025 | Farxiga |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $343.42 | 2019-2025 | Lifevest |
| Medtronic, INC. | $325.98 | 2021-2024 | Symplicity G3, Corevalve Evolut R, Onyx Frontier |
| Astellas Pharma US INC | $195.55 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $193.72 | 2019-2024 | Camzyos, Eliquis |
| Cardiovascular Systems INC. | $190.14 | 2021-2022 | |
| Amgen INC. | $182.17 | 2019-2025 | Repatha |
| Heartflow, INC. | $168.88 | 2023-2024 | Ffrct |
| Janssen Pharmaceuticals, INC | $163.68 | 2019-2023 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $158.83 | 2022-2025 | |
| Cook Medical LLC | $149.67 | 2025 | Zilver Ptx |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $130.41 | 2022-2025 | Amvuttra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.29 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $122.44 | 2021-2022 | |
| Gilead Sciences, INC. | $91.78 | 2019 | |
| Terumo Medical Corporation | $44.61 | 2023 | Glidesheath Slender, Tr Band |
| Sanofi-Aventis U.S. LLC | $41.61 | 2019-2024 | |
| Esperion Therapeutics, INC. | $33.81 | 2020 | |
| Boston Scientific Corporation | $32.91 | 2023 | Watchman Flx |
| Siemens Medical Solutions USA, INC. | $27.70 | 2023-2024 | Artis Icono Biplane, Artis Icono Floor |
| Atricure, INC. | $24.52 | 2022 | |
| Irhythm Technologies, INC. | $18.60 | 2024 | Zio Xt Patch, Zio Monitor |
| Jazz Pharmaceuticals INC. | $17.06 | 2019 | |
| Vifor Pharma, INC. | $14.23 | 2021 | |
| Cvrx, INC. | $13.20 | 2025 | Barostim Neo System |
| Pfizer INC. | $13.03 | 2022 | |
| Amarin Pharma, INC. | $12.90 | 2020 | |
| Mylan Specialty L.P. | $11.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Lieberman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.